The significance of ER and PgR in breast cancer as a prognostic and theranostic marker is well established, but the importance of androgen receptor (AR) is uncertain. A meta-analysis by Vera-Badillo et al. that collected data from 19 studies and 7,693 patients demonstrated that AR positivity was found in 60.5% of breast cancer cases [7]. Here, ESR1 is linked to breast carcinoma.